WS Investor
09 Mar 2026, 19:43
Agilent Technologies announced it has agreed to acquire pathology solutions company Biocare Medical in an all-cash deal valued at $950 million.
Biocare specializes in clinical and research pathology tools, including immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions, and offers more than 300 specialized antibodies used in cancer diagnostics. The company generated more than $90 million in revenue in 2025 and has recorded double-digit revenue and profit growth since 2021.
Agilent said the acquisition will expand its pathology and cancer diagnostics portfolio, strengthen its antibody and reagent offerings, and enhance its ability to serve clinical and research laboratories. The transaction is expected to improve Agilent’s growth rate, margins and recurring non-instrument revenue mix, with earnings per share expected to benefit about 12 months after closing. The deal is expected to close by Agilent’s fourth fiscal quarter of 2026, subject to regulatory approvals.
Biocare specializes in clinical and research pathology tools, including immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions, and offers more than 300 specialized antibodies used in cancer diagnostics. The company generated more than $90 million in revenue in 2025 and has recorded double-digit revenue and profit growth since 2021.
Agilent said the acquisition will expand its pathology and cancer diagnostics portfolio, strengthen its antibody and reagent offerings, and enhance its ability to serve clinical and research laboratories. The transaction is expected to improve Agilent’s growth rate, margins and recurring non-instrument revenue mix, with earnings per share expected to benefit about 12 months after closing. The deal is expected to close by Agilent’s fourth fiscal quarter of 2026, subject to regulatory approvals.
